[1]
|
Moellering, R.C. (2003) Linezolid: The First Oxazolidinone Antimicrobial. Annals of Internal Medicine, 138, 135-142.
https://doi.org/10.7326/0003-4819-138-2-200301210-00015
|
[2]
|
Rubinstein, E., Isturiz, R., Standiford, H.C., et al. (2003) Worldwide Assessment of Linezolid’s Clinical Safety and Tolerability: Comparator Controlled Phase III Studies. Antimicrobial Agents and Chemotherapy, 47, 1824-1831.
https://doi.org/10.1128/AAC.47.6.1824-1831.2003
|
[3]
|
Vinh, D.C. and Rubinstein, E. (2009) Linezolid: A Review of Safety and Tolerability. Journal of Infection, 59, S59- S74. https://doi.org/10.1016/S0163-4453(09)60009-8
|
[4]
|
Oramas-Shirey, M.P., Buchanan, L.V., Dileto-Fang, C.L., et al. (2001) Efficacy of Linezolid in a Staphylococcal Endocarditis Rabbit Model. Journal of Antimicrobial Chemotherapy, 47, 349-352. https://doi.org/10.1093/jac/47.3.349
|
[5]
|
Patel, R., Rouse, M.S., Piper, K.E. and Steckelberg, J.M. (2001) Linezolid Therapy of Vancomycin-Resistant Enterococcus Faeciumexperimental Endocarditis. Antimicrobial Agents and Chemotherapy, 45, 621-623.
https://doi.org/10.1128/AAC.45.2.621-623.2001
|
[6]
|
Tsaganos, T., Skiadas, I., Koutoukas, P. et al. (2008) Efficacy and Pharmacodynamics of Linezolid, Alone and in Combination with Rifampicin, in an Experimental Model of Methicillin-Resistant Staphylococcus Aureus Endocarditis. Journal of Antimicrobial Chemotherapy, 62, 381-383. https://doi.org/10.1093/jac/dkn180
|
[7]
|
Mancino, P., Ucciferri, C., Falasca, K., Pizzigallo, E. and Vecchiet, J. (2008) Methicillin-Resistant Staphylococcus Epidermidis (MRSE) Endocarditis Treated with Linezolid. Scandinavian Journal of Infectious Diseases, 40, 67-73.
https://doi.org/10.1080/00365540701509915
|
[8]
|
Muñoz, P., Rodríguez-Creixéms, M., Moreno, M., et al. (2007) Linezolid Therapy for Infective Endocarditis. Clinical Microbiology and Infection, 13, 211-215. https://doi.org/10.1111/j.1469-0691.2006.01585.x
|
[9]
|
Lauridsen, T.K., Arpi, M. and Bruun, N.E. (2010) Linezolid Therapy for Infectious Endocarditis. Ugeskrift for Læger, 172, 1215-1216.
|
[10]
|
Vardakas, K.Z., Kioumis, I. and Falagas, M.E. (2009) Association of Pharmacokinetic and Pharmacodynamic Aspects of Linezolid with Infection Outcome. Current Drug Metabolism, 10, 2-12.
https://doi.org/10.2174/138920009787048446
|
[11]
|
Gould, F.K. (2011) Linezolid: Safety and Efficacy in Special Populations. Journal of Antimicrobial Chemotherapy, 66, iv3-iv6. https://doi.org/10.1093/jac/dkr071
|
[12]
|
Bressler, A.M., Zimmer, S.M., Gilmore, J.L. and Somani, J. (2004) Peripheral Neuropathy Associated with Prolonged Use of Linezolid. The Lancet Infectious Diseases, 4, 528-531. https://doi.org/10.1016/S1473-3099(04)01109-0.
|